Effects of Anabolic Steroids on Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomised Controlled Trials

Lei Pan1, Manyuan Wang2, Xiaomei Xie3, Changjun Du4, Yongzhong Guo4*

1 Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Binzhou Medical University, Binzhou, China, 2 School of Traditional Chinese Medicine, Capital Medical University, Beijing, China, 3 Department of Radiotherapy, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China, 4 Department of Respiratory Medicine, Xuzhou Central Hospital, Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China

Abstract

Background: Anabolic steroids are known to improve body composition and muscle strength in healthy people. However, whether anabolic steroids improve the physical condition and function in patients with chronic obstructive pulmonary disease (COPD) remains undetermined. A meta-analysis was conducted to review the current evidence regarding the effects of anabolic steroids on COPD patients.

Methods: A comprehensive literature search of PubMed and EMBASE was performed to identify randomised controlled trials that examine the effects of anabolic steroids on COPD patients. Weighted mean differences (WMDs) with 95% confidence intervals were calculated to determine differences between anabolic steroid administration and control conditions.

Results: Eight eligible studies involving 273 COPD patients were identified in this meta-analysis. Significant improvements were found in body weight (0.956 kg), fat-free mass (1.606 kg), St. George’s Respiratory Questionnaire total score (−6.336) and symptom score (−12.148). The apparent improvements in maximal inspiratory pressure (2.740 cmH2O) and maximal expiratory pressure (12.679 cmH2O) were not significant. The effects on handgrip strength, forced expiratory volume in one second (FEV1), predicted FEV1 percent, PaO2, PaCO2 and six-min walk distance were negative, with WMDs of −0.245 kg, −0.096 L/sec, −1.996% of predicted, −1.648 cmHg, −0.039 cmHg and −16.102 meters, respectively.

Conclusions: Limited evidence available from the published literature suggests that the benefit of anabolic steroids on COPD patients cannot be denied. However, further studies are needed to identify the specific benefits and adverse effects of anabolic steroids on COPD patients and to determine the optimal populations and regimes of anabolic steroids in COPD patients.

Citation: Pan L, Wang M, Xie X, Du C, Guo Y (2014) Effects of Anabolic Steroids on Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomised Controlled Trials. PLoS ONE 9(1): e84855. doi:10.1371/journal.pone.0084855

Editor: Ashutosh Nath Aggarwal, Postgraduate Institute of Medical Education and Research, India

Received July 25, 2013; Accepted November 19, 2013; Published January 10, 2014

Copyright: © 2014 Pan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work is supported by the Research Grant from Xuzhou Central Hospital (XZB201227). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: yongzhguo@sina.cn.

These authors contributed equally to this work.

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of chronic disability and mortality worldwide, and is predicted to be the third leading cause of death by 2030 [1]. Considered formerly a disease of the lungs, COPD has significant systemic manifestations, including weight loss, skeletal muscle dysfunction and nutritional abnormalities, which are important determinants of physical capacity, health-related quality of life and increased disability and mortality [2,3]. In contrast to pulmonary dysfunction, weight loss, skeletal muscle dysfunction and reduced exercise capacity can be partially reversed by the appropriate treatment [4], namely, pulmonary rehabilitation, particularly well-accepted exercise training and nutritional supplementation programmes. However, patients with severe COPD have difficulty complying with exercise training programmes, and nutritional supplementation alone may not sufficiently augment the substantial training effects of multidisciplinary pulmonary rehabilitation [5].

Pharmacologic interventions have been recommended as an option for pulmonary rehabilitation in COPD patients [6]. Of note, anabolic steroids, which include testosterone and its derivatives, have been reported to increase the weight, fat-free mass (FFM) and muscle mass/strength of healthy people as well as patients with a number of chronic diseases. Catabolic/anabolic disturbances and low testosterone levels have been found in COPD patients [7–9]. Thus, administration of anabolic steroids to improve the body weight, FFM and muscle mass/strength in COPD patients may bring about significant benefits.
Although a large number of clinical studies have assessed the effects of anabolic steroids on COPD patients in terms of body weight, muscle strength, exercise capacity and quality of life, they do not fully identify the benefits of these compounds. In fact, the last statements on pulmonary rehabilitation by the American Thoracic Society and the European Respiratory Society do not present a confirmative conclusion on the benefit of routine application of anabolic steroids in COPD rehabilitation [10]. Clinical trials do not have sufficient statistical power to detect potential clinical differences in the effects of these steroids on COPD patients because they often feature small sample sizes.

In this study, we conducted a meta-analysis of randomised controlled trials (RCTs) to evaluate the potential benefits of anabolic steroids on COPD patients in terms of body composition (body weight and FFM), muscle strength [maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP) and handgrip strength], pulmonary function [forced expiratory volume in one second (FEV1) and FEV1 percent predicted (FEV1%)], arterial blood gas (PaO2 and PaCO2), exercise capacity [six-min walk distance (6-MWD)] and quality of life as measured by St. George’s Respiratory Questionnaire (SGRQ). The specific aim of the study was to evaluate the overall therapeutic effects of anabolic steroids on COPD.

Materials and Methods

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [11].

Literature search and selection

We comprehensively searched PubMed and EMBASE up to January 2013, limiting the search to clinical trials and humans but without any language restrictions. COPD-associated terms (bronchitis OR COPD OR obstructive pulmonary disease OR obstructive lung disease OR obstructive airway disease OR emphysema OR chronic airflow limitation OR chronic airway obstruction OR forced expiratory volume) and anabolic steroid-associated terms (anabolic OR androgen OR androstenedione OR ghrelin OR growth hormone OR mesterolone OR methandienone OR methandriol OR methenolone OR methandrostenedione OR methyltestosterone OR nandrolone OR norethandrolone OR oxabolone OR oxandrolone OR oxymetholone OR quinabolone OR sex hormone OR stanolone OR stanozolol OR testosterone OR trenbolone) were searched using combined subject and free-text terms. Reference lists of relevant publications were manually searched for additional studies.

Studies were included in this meta-analysis if they met the following criteria: (1) the design was a prospective RCT (regardless of sample size); (2) COPD diagnosis was based on acceptable criteria as determined by pulmonary function tests; (3) patients with established COPD were either given anabolic steroid treatment (regardless of the type and dose) in addition to concurrent therapy or assigned to the control group of the study (non-anabolic steroid treatment or placebo); (4) data needed to be analysed in anabolic steroid and control groups were reported pre- and post-treatment; and (5) the study duration was >3 weeks. If duplicates were found, the study with the larger sample size was included. Studies were excluded if they did not meet the aforementioned criteria or if the information provided was insufficient for data extraction.

Data extraction and quality assessment

Two investigators independently examined the titles, abstracts and complete articles of selected studies that met the inclusion criteria using a standardised protocol. Disagreements were resolved by discussion with a third investigator. Data extracted from each article included the name of the first author, year of publication, nation, patient inclusion criteria, sample size, study duration, intervention and patient characteristics (baseline age, height, weight, body mass index and lung function). When studies reported data for several time intervals, we selected the one with the longest follow-up period for analysis. Studies that separately provided data based on interventional methods were pooled as independent studies. If medians and interquartile ranges were provided instead of means and standard deviations (SDs), the corresponding SDs were calculated according to the method described by Hozo et al. [12].

The methodological quality of each study was assessed using the Physiotherapy Evidence Database (PEDro) scale [13] (http://www.pedro.org.au/english/downloads/pedro-scale/). To minimise selection bias, two investigators rated each study independently and subsequently assigned a score based on the PEDro scale.

Statistical analysis

The meta-analysis was conducted using Stata statistical software (Version 10.0, Stata Corporation, College Station, TX, USA). The results were pooled using weighted mean differences (WMDs) with corresponding 95% confidence intervals (CI). Q and I² statistics were used to examine statistical heterogeneity amongst individual studies. I² heterogeneity <0.10 or I² >60% indicated significant heterogeneity. If significant heterogeneity was observed, we used a random effects model to analyse the pooled results; otherwise, a
fixed effects model was used. Sensitivity (including omitting one study at a time and changing the eligibility criteria) (the number of studies ≥5) and subgroup analyses were conducted to determine the robustness of the pooled results and to explore the possible sources of heterogeneity. Publication bias was evaluated visually using a funnel plot and statistically using Egger’s and Begg’s tests (the number of studies ≥5). A two-tailed value of P<0.05 was considered statistically significant.

Results

Characteristics of included studies

The selection process for the studies included in the meta-analysis is outlined in Figure 1. Eight articles [9,14–20], including 9 RCTs (with one article [9] reporting two separate trials), involving 273 patients met the inclusion criteria for this meta-analysis. The characteristics of the included studies are provided in Table 1. The patient characteristics of the included studies are listed in Table 2. The mean PEDro score of the 9 trials was 6.8 (SD = 0.83), and detailed results were summarized in Table 3.

Results of pooled analysis

The pooled results indicated that an increase trend in body weight, FFM, MIP and MEP was observed after anabolic steroid administration, but decrease in handgrip strength, FEV1, FEV1%, PaO2, PaCO2, 6-MWD, SGRQ total and symptom score. The detailed results of the pooled analysis are presented in Table 4.

Five [14,16–18,20] the six RCTs [14,16–20] reported an increase in body weight after anabolic steroid administration compared with that under control conditions (ranging from −0.08 to 2.63). The pooled result was significant (WMD, 0.956 kg; 95% CI: 0.370 to 1.533) without significant heterogeneity (I² = 0.0%, F = 0.0%). The result of the random effects model remained statistically significant (WMD, 0.891 kg; 95% CI: 0.078 to 1.703).

Change in FFM is presented in seven RCTs [9,14–19], six of which showed significant increase after anabolic steroid administration [9,14–18]. Pooled analysis of the overall data produced statistically significant results (WMD, 1.606 kg; 95% CI: 1.131 to 2.082, identical in fixed and random effect models) without significant heterogeneity (P heterogeneity = 0.774, F = 0.0%).

Significant increase in MIP and MEP after anabolic steroid administration were observed using a fixed models (WMD, 3.090 cmH2O; 95% CI: 1.059 to 5.121; P heterogeneity = 0.059, I² = 0.0%). However, the increase trend was not significant using a random effects model. (WMD, 2.740 cmH2O; 95% CI: −1.375 to 6.855; vs. WMD, 12.679 cmH2O; 95% CI: −2.074 to 27.432).

The pooled result for grip strength demonstrated non-significant decrease (WMD, −0.245 kg; 95% CI: −0.770 to 0.281, identical in fixed and random effect models) without significant heterogeneity (P heterogeneity = 0.609, F = 0.0%), which was consistent with all three RCTs included in this meta-analysis [15,17,19].

Table 1. Characteristics of studies included in this meta-analysis.

| Study         | National   | Study design | Inclusion criteria                                                                 | Treatment intervention                                                                 | Duration | Drop off |
|---------------|------------|--------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|----------|----------|
| Schols 1995   | Netherlands| RCT, DB      | Stable COPD; moderate to severe                                                     | Nandrolone 50 mg (men)/25 mg (women) I.m. every 2 weeks for 6 weeks + rehabilitation program (exercise training and nutritional intervention) | 8W       | NR/NR    |
| Burdet 1997   | Switzerland| RCT, DB      | FEV1/FVC (% pred) <70% increase in FEV1 (% pred) <10% after inhalation of 400 mg of albuterol; BMI <90 % of ideal body weight | rhGH 0.15 IU/kg subcutaneous injection daily for 21 days + rehabilitation program including exercise training | 13W      | 0/0      |
| Ferreira 1998 | Canada     | RCT, DB      | Male, stable COPD, BMI <20 kg/m², MIP <60% of the predicted value                   | Oestosterone 25 mg I.m. at baseline; stanozolol 12 mg po every day for 27 weeks + rehabilitation (cycle ergometry and inspiratory muscle training) | 27W      | 3/3      |
| Creutzberg 2003 | Netherlands| RCT, DB      | Stable COPD; FEV1 (% pred) <70%; increase in FEV1 <10% of predicted value after inhalation of a 2-agonist | Nandrolone 50 mg I.m. every 2 weeks for 8 weeks + standardized pulmonary rehabilitation | 8W       | 5/2      |
| Casaburi 2004 | United States| RCT         | Stable COPD; age 55-80 years; FEV1 (% pred) ≥60%; FEV1/VC (% pred) ≥60 %            | Testosterone 100 mg I.m. every week for 10 weeks + resistance exercise training or not | 10W      | 3/1T/1T(N) |
| Svartberg 2004 | Norway     | RCT, DB      | Stable COPD; FEV1 (% pred) <60 %                                                  | Testosterone 250 mg I.m. every 4 weeks for 26 weeks                                   | 26W      | 1/1      |
| Sharma 2008   | Canada     | RCT, DB      | Stable COPD; FEV1 (% pred) <50%; FEV1/FVC (% pred) <0.7                          | Nandrolone 50 mg (M) or 25 mg (F) I.m. every 2 weeks + physical training              | 8W       | 0/0      |
| Miki 2012     | Japan      | RCT, DB      | Stable COPD; age 20-85 years; FEV1/FVC (% pred) <70%; FEV1 (% pred) ≤50%; BMI <21 (kg/m²) | Ghrelin 2 mg/kg, iv. twice a day for 3 weeks + rehabilitation                           | 7W       | 4/2      |

BMI = body mass index; COPD = chronic obstructive pulmonary disease; DB = double-blind; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; MEP = maximal expiratory pressure; MIP = maximal inspiratory pressure; N = non-training group; NR = not reported; RCT = randomized controlled trial; T = training group; % pred = percentage of predicted value.

doi:10.1371/journal.pone.0084855.t001
Table 2. The patient characteristics of the included studies.

| Study                  | Age (years) | Height (cm) | Weight (kg) | BM (kg/m²) | FEV₁ (L/sec) | FVC (% predicted) | FEV₁/FVC (%) | PO₂ (mmHg) | PO₂ (mmHg) | PₐO₂ (mmHg) | PₐCO₂ (mmHg) | BMI (kg/m²) |
|------------------------|-------------|-------------|-------------|------------|--------------|-------------------|---------------|-------------|-------------|--------------|--------------|--------------|
| Schols 1995 [14]       | 66.9        | 165.2       | 64.9        | 20.6 (12.0) | 70.5 (60.5)  | 118.9 (101.2)     | 0.85 (0.65)   | 112.1       | 95.3        | 4.25         | 4.00         | 20.6 (12.0)  |
| Burdet 1997 [15]       | 66.7        | 167.0       | 65.3        | 20.3 (12.0) | 70.5 (60.5)  | 117.2 (101.2)     | 0.84 (0.65)   | 112.0       | 95.2        | 4.24         | 4.00         | 20.3 (12.0)  |
| Creutzberg 2003 [17]   | 66.5        | 168.3       | 67.1        | 21.2 (13.0) | 70.5 (60.5)  | 115.5 (101.2)     | 0.82 (0.65)   | 111.5       | 95.1        | 4.23         | 4.00         | 21.2 (13.0)  |
| Casaburi 2004 (N) [9]  | 67.0        | 168.0       | 68.6        | 21.8 (14.0) | 70.5 (60.5)  | 113.0 (101.2)     | 0.80 (0.65)   | 111.0       | 95.0        | 4.21         | 4.00         | 21.8 (14.0)  |
| Casaburi 2004 (T) [9]  | 67.0        | 168.0       | 69.6        | 21.8 (14.0) | 70.5 (60.5)  | 113.0 (101.2)     | 0.80 (0.65)   | 111.0       | 95.0        | 4.21         | 4.00         | 21.8 (14.0)  |
| Svartberg 2004 [18]    | 67.0        | 167.0       | 68.1        | 21.7 (14.0) | 70.5 (60.5)  | 112.0 (101.2)     | 0.80 (0.65)   | 111.0       | 95.0        | 4.21         | 4.00         | 21.7 (14.0)  |
| Sharma 2008 [19]       | 70.5        | 168.0       | 67.0        | 21.8 (14.0) | 70.5 (60.5)  | 112.0 (101.2)     | 0.80 (0.65)   | 111.0       | 95.0        | 4.21         | 4.00         | 21.8 (14.0)  |
| Miki 2012 [20]         | 70.5        | 168.0       | 67.0        | 21.8 (14.0) | 70.5 (60.5)  | 112.0 (101.2)     | 0.80 (0.65)   | 111.0       | 95.0        | 4.21         | 4.00         | 21.8 (14.0)  |

Values are mean (SD). BMI = body mass index; DB = double-blind; FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; MEP = maximal expiratory pressure; MIP = maximal inspiratory pressure; NR = not reported; PO₂ = arterial partial pressure of oxygen; PO₂ = arterial partial pressure of carbon dioxide; SGRQ = St George’s Respiratory Questionnaire; WMD = weighted mean difference.

PaCO₂ was found to have be decreased using a random effects model (WMD, 0.087 kg; 95% CI: 0.335 to 1.594; P(heterogeneity) = 0.081, F = 51.9%). The pooled result failed to show improvement in PO₂ using both a random (WMD, −1.648 mmHg; 95% CI: −4.811 to 1.515) and a fixed effects model (WMD, −1.035 mmHg; 95% CI: −2.837 to 0.767). On the other hand, PaCO₂ was found to have be decreased using a random effects model (WMD, −0.039 mmHg; 95% CI: −2.205 to 2.216), which was opposite to the results obtained using a fixed effects model (WMD, 0.275 mmHg; 95% CI: −0.963 to 1.514).

Two studies [17,20] reported the effects of anabolic steroids on the quality of life as measured by SGRQ scores. Our analysis for total and symptom SGRQ demonstrated significant effects with decreases of 6.336 (95% CI: 4.431 to 8.241; P(heterogeneity) = 0.0894, F = 0.0%) and 12.148 (95% CI: 9.552 to 14.743; P(heterogeneity) = 0.579, F = 0.0%), identical in fixed and random effect models.

The results of sensitivity and subgroup analyses

Given the fact that the number of study is small in this meta-analysis, sensitivity and subgroup analyses were performed only for body weight, FFM, MIP and 6-MWD.

Sensitivity analyses by omitting one study at a time were conducted to identify the robustness of results. Our results indicated that WMDs for body weight ranged from 0.422 kg (95% CI: −0.270 to 1.113) to 1.192 kg (95% CI: 0.539 to 1.847) when the RCTs by Ferreira [16] and Schols [14] were omitted; FFM ranged from 1.343 kg (95% CI: 0.690 to 1.998) to 1.700 kg (95% CI: 1.194 to 2.205) when the RCTs by Svartberg [18] and Schols [14] were omitted; MIP ranged from 1.542 kg (95% CI: 0.640 to 1.969; P(heterogeneity) = 0.0%) to 2.837 kg (95% CI: 0.640 to 1.969); 6-MWD ranged from 24.20 meters (95% CI: 21.953 to 24.878; P(heterogeneity) = 0.018, I² = 0%) to 28.878 meters (95% CI: 28.030 to 38.875; P(heterogeneity) = 0.055, I² = 0.112, 95% CI: 0.028 to 0.219 vs. WMD, 0.087 kg; 95% CI: 0.335 to 1.594; P(heterogeneity) = 0.081, F = 51.9%), respectively.

When the RCTs by Svartberg [18] and Casaburi (no-training) [9], in which treatment intervention was free of pulmonary rehabilitation or exercise training, were omitted, the values of WMD for body weight, FFM, MIP and 6-MWD were 0.965 kg (95% CI: 0.335 to 1.594; P(heterogeneity) = 0.081, F = 51.9%), 1.304 kg (95% CI: 0.640 to 1.969; P(heterogeneity) = 0.802, F = 0.0%), 1.779 cmH₂O (95% CI: −3.049 to 6.608; P(heterogeneity) = 0.055, F = 53.8%) and −21.953 meters (95% CI: −72.784 to 28.878; P(heterogeneity) = 0.018, F = 70.3%), respectively.

When one RCT by Burdet [15], in which anabolic steroid use was recombinant human growth hormone (GH), and one by Miki [20], in which ghrelin was used, were disregarded, the values of WMD for body weight, FFM, MIP and 6-MWD were 1.380 kg (95% CI: 0.425 to 2.334; P(heterogeneity) = 0.058, F = 56.1%), 1.672 kg (95% CI: 1.160 to 2.183; P(heterogeneity) = 0.732, F = 0.0%), 4.294 cmH₂O (95% CI: −0.811 to 8.668; P(heterogeneity) = 0.074, F = 53.8%) and −20.276 meters (95% CI: −42.558 to 2.005; P(heterogeneity) = 0.112, F = 60.4%), respectively.

Duration of therapy is an important factor influencing the effects of anabolic steroids on COPD [20]. Subgroup analysis based on therapy duration showed that compared with therapy duration of <10 weeks, therapy duration of ≥10 weeks resulted in greater improvements in body weight (WMD, 1.542 kg; 95% CI: 0.037 kg; 95% CI: 0.219 to 2.334), which was opposite to the results obtained using a fixed effects model (WMD, 1.035 mmHg; 95% CI: −0.963 to 1.514).
In this meta-analysis, we summarised findings in the clinical literature on the effects of anabolic steroid administration on COPD patients. The results revealed significant improvements in body weight, FFM and quality of life after anabolic steroid administration, no significant change in MIP and MEP, and

### Discussion

In this meta-analysis, we summarised findings in the clinical literature on the effects of anabolic steroid administration on COPD patients. The results revealed significant improvements in body weight, FFM and quality of life after anabolic steroid administration, no significant change in MIP and MEP,

#### Publication bias

As shown in the funnel plots of Figure 3, no publication bias was found for body weight, FFM, MIP and 6-MWD (Egger’s test: \( P = 0.643, P = 0.786, P = 0.716, P = 0.539 \), respectively, and Begg’s test: \( P = 1.000, P = 0.711, P = 0.548, P = 0.806 \), respectively). Given the limited number of studies, assessment of publication bias was not conducted for MEP, handgrip strength, FEV1, FEV1%, PaO2, PaCO2, SGRQ total and symptom score.

### Table 3. Quality score of selected studies by the PEDro.

| Study             | Random allocation | Concealed location | Baseline similar | Blinding (subject) | Blinding (therapist) | Blinding (assessor) | Measures for >85% comparison | ITT Group | Point Total |
|-------------------|-------------------|--------------------|------------------|-------------------|---------------------|---------------------|-----------------------------|-----------|-------------|
| Schols 1995 [14]  | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 6           |
| Burdet 1997 [15]  | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 8           |
| Ferreira 1998 [16] | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 6           |
| Creutzberg 2003 [17] | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 7           |
| Casaburi 2004 (N) [9] | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 7           |
| Casaburi 2004 (T) [9] | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 7           |
| Svartberg 2004 [18] | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 6           |
| Sharma 2008 [19]  | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 6           |
| Miki 2012 [20]    | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | \( \checkmark \) | 8           |

| ITT = Intention-to-treat analysis; N = non-training group; PEDro = physiotherapy evidence database; T = training group; \( \checkmark \) = PEDro criteria met; \( \times \) = PEDro criteria not met.

#### Table 4. The results of pooled analyses.

| No. study                  | Heterogeneity \( I^2 \) | WMD (95% CI) |
|----------------------------|--------------------------|--------------|
|                            | Random effects           | Fixed effects|
| Body weight, kg            | 0.139 (0.60–0.99)        | 0.539 (0.08–1.00) |
| FFM, kg                    | 0.074 (0.59–1.00)        | 0.109 (0.60–1.60) |
| MIP, cmH2O                 | 0.059 (0.50–1.00)        | 0.059 (0.50–1.00) |
| MEP, cmH2O                 | 0.190 (0.50–1.00)        | 0.190 (0.50–1.00) |
| Grip strength, kg          | 0.609 (0.40–0.80)        | 0.609 (0.40–0.80) |
| FEV1, L/sec                | 0.491 (0.20–0.70)        | 0.491 (0.20–0.70) |
| FEV1, % predicted          | 0.207 (0.10–0.30)        | 0.207 (0.10–0.30) |
| PaO2, mmHg                 | 0.070 (0.50–1.00)        | 0.070 (0.50–1.00) |
| PaCO2, mmHg                | 0.034 (0.10–0.30)        | 0.034 (0.10–0.30) |
| 6-MWD, meter               | 0.037 (0.00–0.20)        | 0.037 (0.00–0.20) |
| SGRQ (total score)         | 0.894 (0.20–0.30)        | 0.894 (0.20–0.30) |
| SGRQ (symptom)             | 0.579 (0.00–0.10)        | 0.579 (0.00–0.10) |

| FEV1 = forced expiratory volume in one second; FFM = fat-free mass; FVC = forced vital capacity; MIP = maximal expiratory pressure; MEP = maximal inspiratory pressure; PaO2 = arterial oxygen pressure; PaCO2 = arterial carbon dioxide pressure; SGRQ = St. George’s Respiratory Questionnaire; T/C = treatment and control group; 6-MWD = 6-min walking distance.

doi:10.1371/journal.pone.0084855.t003

0.512 to 2.573; \( P_{\text{heterogeneity}} = 0.260, \ I^2 = 25.8\% \) vs. WMD, 0.268 kg; 95% CI: \(-0.548 to 1.084\); \( P_{\text{heterogeneity}} = 0.940, \ I^2 = 0.0\% \) and FFM (WMD, 1.813 kg; 95% CI: 1.245 to 2.382; \( P_{\text{heterogeneity}} = 0.796, \ I^2 = 0.0\% \) vs. WMD, 1.126 kg; 95% CI: \(-0.260 to 1.992\); \( P_{\text{heterogeneity}} = 0.042, \ I^2 = 68.5\% \) vs. WMD, 2.740 cm H2O; 95% CI: \(-1.375 to 6.855\); \( P_{\text{heterogeneity}} = 0.169, \ I^2 = 40.5\% \) and 6-MWD (WMD, \(-35.198\) meters; 95% CI: \(-75.254 to 4.858\); \( P_{\text{heterogeneity}} = 0.102, \ I^2 = 56.2\% \) vs. WMD, 21.265 meters; 95% CI: \(-13.454 to 55.984\); \( P_{\text{heterogeneity}} = 0.430, \ I^2 = 0.0\% \).

Since most RCTs had relatively small sample size, a cumulative meta-analysis was conducted to explore the effects of sample size on overall effect size. We found that sample size may influence the effect size of 6-MWD, but not of body weight, FFM and MIP (Figure 2).
negative change in handgrip strength, pulmonary function, arterial blood gas and exercise capacity.

The observed increases in body weight and FFM after anabolic steroid use may not be a chance finding based on the pharmacodynamics of anabolic steroids. Most studies that included control [9,14–18] and non-control trials [21,22] have consistently reported an increase trend in body weight and FFM. In agreement with previous observations [14,16,22], our results show that the magnitude of increase in FFM is larger than that in body weight. This result supports the hypothesis that anabolic steroid-induced weight gain is mainly due to an increase in FFM rather than increased fat mass and water retention. This result also contradicts findings on nutritional supplementation, in which weight gain is generally attributed to an increase in fat mass rather than in FFM. The results of this meta-analysis therefore provide the reliable evidence that anabolic steroid in improving body weight and FFM is superior to nutritional supplementation in patients with COPD. As the main component of muscles, FFM is significantly associated with muscle strength, pulmonary function, physical performance, quality of life and survival in COPD patients [23–26]. However, the effects of anabolic steroid on these factors were largely insignificant or missing in this meta-analysis. Additional large-scale studies are needed to determine whether or not improvement in FFM can translate to functional benefits and prolonged survival.

Sensitivity analysis confirmed the robustness of the pooled analyses for body weight and FFM. No statistical heterogeneity and publication bias were found for body weight and FFM, indicating that it would not influence the results in favor of anabolic steroid in COPD patients. Thus, results in the improvement of body weight and FFM should be regarded with a higher degree of certainty.

Theoretically, anabolic steroids can affect all types of skeletal muscles. The results show differences between MIP and MEP and handgrip, possibly reflecting a difference between respiratory muscles and peripheral limb muscles. The application of nutritional supplementation to stabilise COPD also shows similar results [27]. Marked physiological differences between respiratory muscles and peripheral limb muscles have been previously reported, including muscle phenotypic expression, fatigue resistance, reversal of fatigue and muscle remodelling. However, no experimental evidence to support the different effects of anabolic steroids has been found to date. Previous study [17] reported a significant increase in handgrip strength after anabolic steroid administration that was not observed in our study. The significant differences in the effects of anabolic steroids on respiratory muscles and peripheral limb muscles cannot be explained based on current evidences and thus require further study.

COPD is characterised by progressive airflow limitation, as reflected by an accelerated decline in lung function. No pharmacotherapy has yet been conclusively shown to reduce this decline. In agreement with previous studies [14,16,18,21,22], the pooled results of this meta-analysis show that treatment with anabolic steroids does not improve pulmonary function and arterial blood gas.

Exercise intolerance is a major symptom of patients with COPD. In contradiction to the previously reported positive effects of exercise training [28,29] and nutritional supplementation [27], this meta-analysis did not find improvements in exercise capacity,
measured by 6-MWD, in the anabolic steroid-administration group compared with that in the control group as. However, a number of non-controlled trials have reported improvement in 6-MWD after anabolic steroid administration when compared with that pre-treatment [18,20,22]. Sensitivity and subgroup analyses in this meta-analysis gave equivocal results for 6-MWD. An addition, significant heterogeneity and the possible small-study effects may increase instability of the current results. Therefore, it is difficult to rule out a positive outcome of anabolic steroid treatment for exercise capacity based on existing evidence.

In contrast to the conclusion of clinical practice guidelines [30], this meta-analysis suggests that anabolic steroid administration improves the quality of life as measured by SGRQ total and symptom scores. Moreover, previous studies have reported improvements in the quality of life as measured by the Medical Research Council [20] and Karnofsky performance status scores [22] after anabolic steroid administration. As the main treatment destination for COPD patients, the improvement in quality of life with steroid use is a clinically promising outcome. However, given the small sample sizes in the studies analysed, additional trials must be conducted to better assess the significance of these effects.

Exercise training is considered to be an essential and mandatory component of pulmonary rehabilitation. However, whether a combined intervention (anabolic steroid plus exercise) results in more beneficial effects remains unclear. Only one RCT [9] directly compared the different effects of anabolic steroid administration with and without exercise in patients with COPD to date, and it reported beneficial effects for the former. The results from our meta-analysis indicated that restricting the analysis to studies that reported a combined intervention did not significantly change the results for body weight and FFM. Our results further suggest that additive increase in body weight and FFM occur when anabolic steroid administration is combined with exercise, which is consistent with previous opinion [31]. Due to limitations of the number of trials, more analyses were not conducted to evaluate the different effects of anabolic steroid administration with and without exercise.

The effects of anabolic steroid therapy on COPD are diverse. Besides those mentioned above, some beneficial effects, such as increase in maximum leg press strength [9] and sexuality [18], have been reported. It should be noted that anabolic steroid administration is accompanied by various adverse events, ranging from cardiovascular events to hepatotoxic, renal, gastrointestinal and endocrine effects. These side effects are generally dose-related. In clinical practice, all of these adverse events must be considered. In the clinical trials included in this meta-analysis, only one trial involving the use of human growth hormone-releasing hormone reported a significant indisposition of the gastrointestinal tract [15]. Other studies reported mild and reversible effects without clinical significance. Given the limited data available, we did not conduct a pooled analysis on the adverse events of anabolic steroids, which should be conducted in future works.

As a systematic review, some limitations must be noted when interpreting the findings of this meta-analysis. First, the small number of patients and studies is a major limitation, particularly when determining the effects of steroid use on MEP, handgrip strength, pulmonary function, arterial blood gas, exercise capacity and quality of life. Thus, selection and publication biases can not be excluded. Because of the limited number of studies, the small-study effects and publication bias were analyzed only for body weight, FFM, MIP and 6-MWD, and more appropriate analyses were not conducted. Second, whilst most of the studies attempted to control potential confounders, a high degree of disparity was observed amongst these factors, including patient characteristics,

Figure 3. Funnel plots demonstrating publication bias for body weight (A), fat-free mass (B), maximal inspiratory pressure (C) and six-min walk distance (D).
doi:10.1371/journal.pone.0084855.g003
drug selection, disease severity, treatment model and follow-up duration, amongst others. Insufficient analyses have been conducted on body weight, FFM, MIP and 6-MWD from a limited number of studies to identify the possible effects of these confounders. More and stronger analyses are required. Third, with all meta-analyses, the risk of heterogeneity must be considered. A potential weakness of the study is that significant heterogeneity was observed in many pooled variables amongst studies. Third, although the existence of statistical heterogeneity was only found for MIP, PO2, PO2 and 6-MWD, no consistent determinant was identified, despite the use of appropriate meta-analytic methods. All of these caveats could lead to false or spurious results, reduced statistical power or even negated present conclusions.

The main implication of this meta-analysis is that anabolic steroid can improve body weight and FFM in patients with COPD, and more benefits are gained from longer-term treatment. Considering the importance of increased body weight and FFM in patients with COPD, the results of this meta-analysis are of high clinical relevance.

In conclusion, anabolic steroids can reverse a number of deteriorated physical conditions/functions in COPD patients, particularly by improving body weight and FFM. Given the positive association between increased FFM and some physical conditions/functions, the beneficial effects of anabolic steroids in COPD patients cannot be prematurely denied. Future studies should be conducted to identify the specific benefits and adverse effects of anabolic steroids in COPD patients and to determine the optimal populations and regimes for which anabolic steroid therapy may be most beneficial.

Supporting Information

Checklist S1 PRISMA 2009 checklist in this meta-analysis.

(DOC)

Figure S1 PRISMA 2009 Flow diagram of study selection.

(DOC)

Author Contributions

Conceived and designed the experiments: YZG. Performed the experiments: LP MYW XMX CJD. Analyzed the data: LP XMX YZG. Contributed reagents/materials/analysis tools: LP MYW CJD. Wrote the paper: MYW XMX YZG.

References

1. WHO (2008) World health statistics 2008. Available: http://www.who.int/whosis/whostat/EN+WHS08_Full.pdf. Accessed 16 June 2013.
2. Hallin R, Gudmundsson G, Suppli UC, Nieminen MM, Gislason T, et al. (2007) Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 101: 1954–1960.
3. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG (1996) Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153: 961–966.
4. Schols AM, Slagen J, Volovics L, Wouters EF (1996) Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1791–1797.
5. GOLD (2012) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available: http://www.goldcopd.org/. Accessed 2013 Jun 18.
6. Nici L, Donner C, Wouters E, Zuo Zuiack R, Ambrosino N, et al. (2006) American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 173: 1390–1413.
7. Deh Hagare K, Marquim K, Gote CH, Tremblay RR, Michaud A, et al. (2003) Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 124: 83–89.
8. Balasubramanian V, Naing S (2012) Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr Opin Pulm Med 18: 112–117.
9. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, et al. (2004) Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 870–878.
10. Spruit MA, Singh SJ, Garvey C, Zuwallack R, Nici L, et al. (2013) An official american thoracic society/european respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188: e13–e64.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2502.
12. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5: 13.
13. Maher CG, Sherrington C, Herbert RD, Mooney EA, Eakin M (2003) Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther 83: 731–721.
14. Schols AM, Soeters PB, Mostert R, Pijpers R, Wouters EF (1995) Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 152: 1268–1274.
15. Bredel L, de Muralt B, Schutz Y, Richard C, Fitting JW (1997) Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomised, controlled study. Am J Respir Crit Care Med 156: 1800–1806.
16. Ferreira IM, Verrechia ET, Nery LE, Goldstein RS, Zamel N, et al. (1996) The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 114: 19–28.
17. Creutzberg EC, Wouters EF, Mostert R, Pijpers R, Schols AM (2003) A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 124: 1733–1742.
18. Svarberg J, Aasbo U, Hjalmarsen A, Sundsfjord J, Jorde R (2004) Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 98: S96–S93.
19. Sharma S, Arneja A, McLean L, Duquetten D, Leslie W, et al. (2000) Anabolic steroids in COPD: a review and preliminary results of a randomized trial. Chron Respir Dis 3: 169–176.
20. Miki K, Mackora R, Nagaya N, Nakazato M, Kimura H, et al. (2012) Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS One 7: e57076.
21. Page GS, Friedman M, Underwood LE, Clemmons DR (1993) The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 99: 1495–1500.
22. Yeh SS, Do Guzman B, Kramer T (2002) Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122: 421–428.
23. Eisser MD, Blanc PD, Sidney S, Yelin EH, Lathon PV, et al. (2007) Body composition and functional limitation in COPD. Respir Res 8: 7.
24. Vestbo J, Prescott E, Ainld J, Dahl M, Nordstaedt BG, et al. (2006) Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173: 79–83.
25. Schols AM, Broekhuizen R, Welings-Scheepers GA, Wouters EF (2005) Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82: 55–59.
26. Ichaki E, Papatheodorou G, Gaki E, Papa L, Koulouris N, et al. (2007) Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 132: 164–169.
27. Ferreira IM, Brooks D, White J, Goldstein R (2012) Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12: D9980.
28. Van JHI, Guo YZ, Yao HM, Pan L (2013) Effects of Tai Chi in patients with chronic obstructive pulmonary disease: preliminary evidence. PLoS One 8: e61006.
29. Franssen FM, Broekhuizen R, Janssen PP, Wouters EF, Schols AM (2004) Effects of whole-body exercise training on body composition and functional capacity in normal-weight patients with COPD. Chest 125: 2021–2028.
30. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, et al. (2007) American Thoracic Society/European Respiratory Society statement: key concepts and regimes for which anabolic steroid may be considered in the treatment regime of selected chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 18: 118–124.